Here are five key notes:
1. The grant will support development and commercialization for Bacterin’s next generation of demineralized bone matrix allografts.
2. The new products will be designed to produce faster and more complete bone healing compared to currently available therapies. The goal is improved clinical outcomes.
3. Mark Schallenberger, MS, is the principal investigator for the project with four others as contributing investigators. The award will finalize product development and fund the pre-clinical studies to support technology commercialization.
4. The Montana Board of Research and Commercialization Technology has given Bacterin two previous grants. Including the most recent grant, the organization has given $458,458 in total financial support.
5. Xtant Medical is focused on regenerative medicine for orthopedic and neurological surgeons.
More articles on orthopedic devices:
Exactech’s new revision hip implant used in 1st surgeries: 5 key notes
Invuity introduces new illuminated retractor system
Nanovis Spine receives NIH research grant
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
